These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26009700)

  • 1. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
    Zhang YW
    World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
    Miranda O; Farooqui M; Siegfried JM
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
    Della Corte CM; Fasano M; Papaccio F; Ciardiello F; Morgillo F
    Biomedicines; 2014 Nov; 2(4):345-358. PubMed ID: 28548075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET targeted therapy for lung cancer: clinical development and future directions.
    Feng Y; Ma PC
    Lung Cancer (Auckl); 2012; 3():53-67. PubMed ID: 28210125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MET axis as a therapeutic target.
    Sattler M; Salgia R
    Update Cancer Ther; 2009 Apr; 3(3):109-118. PubMed ID: 20368753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
    Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
    Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
    Kawakami H; Okamoto I
    Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
    Sylvester PW
    Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.
    Gaudino G; Yang H; Carbone M
    Biomedicines; 2014 Nov; 2(4):327-344. PubMed ID: 28548074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.
    Zhang Y; Xia M; Jin K; Wang S; Wei H; Fan C; Wu Y; Li X; Li X; Li G; Zeng Z; Xiong W
    Mol Cancer; 2018 Feb; 17(1):45. PubMed ID: 29455668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of MET: a double life between normal tissue repair and tumor progression.
    Petrini I
    Ann Transl Med; 2015 Apr; 3(6):82. PubMed ID: 25992381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.
    Smyth EC; Sclafani F; Cunningham D
    Onco Targets Ther; 2014; 7():1001-14. PubMed ID: 24959087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.